Cargando…
Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies
Allogeneic haploidentical HSCT (haplo-HSCT) and unrelated umbilical cord blood transplantation(UCBT)are used in patients lacking HLA-identical sibling or unrelated donors. With myeloablative condition and GVHD prophylaxis of using low-dose ATG and post-transplantation cyclophosphamide (PTCY), we con...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599442/ https://www.ncbi.nlm.nih.gov/pubmed/34804017 http://dx.doi.org/10.3389/fimmu.2021.733326 |
_version_ | 1784600957286350848 |
---|---|
author | Li, Hua Li, Xiaofan Chen, Yiling Li, Duihong Chen, Xianling Zhu, Zhijuan Wang, Yiting Huang, Jiafu Chen, Ping Chen, Yuanzhong Li, Nainong |
author_facet | Li, Hua Li, Xiaofan Chen, Yiling Li, Duihong Chen, Xianling Zhu, Zhijuan Wang, Yiting Huang, Jiafu Chen, Ping Chen, Yuanzhong Li, Nainong |
author_sort | Li, Hua |
collection | PubMed |
description | Allogeneic haploidentical HSCT (haplo-HSCT) and unrelated umbilical cord blood transplantation(UCBT)are used in patients lacking HLA-identical sibling or unrelated donors. With myeloablative condition and GVHD prophylaxis of using low-dose ATG and post-transplantation cyclophosphamide (PTCY), we conducted a prospective clinical trial. Of eligible 122 patients from February 2015 to December 2019 in the study, 113 patients were involved. Forty-eight patients were in the group of sequential haplo-cord transplantation (haplo-cord HSCT), and 65 patients were in the group of single UCBT. The primary endpoint of 2-year disease-free survival (DFS) was no statistical difference between groups (64.1 vs. 56.5%), p>0.05. The analysis of subgroup patients with relapsed/refractory showed haplo-cord HSCT was associated with better OS (HR 0.348, 95% CI, 0.175–0.691; p=0.0025), DFS (HR 0.402, 95% CI, 0.208–0.779; p=0.0069), and GRFS (HR 0.235, 95% CI, 0.120–0.457, p<0.0001) compared to the single cord group. The 2-year’s probability in OS, DFS, and GRFS was 64.9 vs. 31.6%, 64.5 vs. 31.6%, and 60.8 vs. 15.0% in the haplo-cord group and single cord group, respectively. III-IV acute GVHD 8.3 vs. 6.2%, chronic GVHD 25.8 vs. 13.7%, and extensive chronic GVHD 5.3 vs. 1.8% were shown in corresponding group, p>0.05. The patients engrafted persistently with UCB showed better survival outcomes. Our sequential Haplo-cord HSCT with ATG/PTCY improved the survival of patients and might be an alternative transplantation approach for patients with relapsed/refractory hematologic malignancies. |
format | Online Article Text |
id | pubmed-8599442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85994422021-11-19 Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies Li, Hua Li, Xiaofan Chen, Yiling Li, Duihong Chen, Xianling Zhu, Zhijuan Wang, Yiting Huang, Jiafu Chen, Ping Chen, Yuanzhong Li, Nainong Front Immunol Immunology Allogeneic haploidentical HSCT (haplo-HSCT) and unrelated umbilical cord blood transplantation(UCBT)are used in patients lacking HLA-identical sibling or unrelated donors. With myeloablative condition and GVHD prophylaxis of using low-dose ATG and post-transplantation cyclophosphamide (PTCY), we conducted a prospective clinical trial. Of eligible 122 patients from February 2015 to December 2019 in the study, 113 patients were involved. Forty-eight patients were in the group of sequential haplo-cord transplantation (haplo-cord HSCT), and 65 patients were in the group of single UCBT. The primary endpoint of 2-year disease-free survival (DFS) was no statistical difference between groups (64.1 vs. 56.5%), p>0.05. The analysis of subgroup patients with relapsed/refractory showed haplo-cord HSCT was associated with better OS (HR 0.348, 95% CI, 0.175–0.691; p=0.0025), DFS (HR 0.402, 95% CI, 0.208–0.779; p=0.0069), and GRFS (HR 0.235, 95% CI, 0.120–0.457, p<0.0001) compared to the single cord group. The 2-year’s probability in OS, DFS, and GRFS was 64.9 vs. 31.6%, 64.5 vs. 31.6%, and 60.8 vs. 15.0% in the haplo-cord group and single cord group, respectively. III-IV acute GVHD 8.3 vs. 6.2%, chronic GVHD 25.8 vs. 13.7%, and extensive chronic GVHD 5.3 vs. 1.8% were shown in corresponding group, p>0.05. The patients engrafted persistently with UCB showed better survival outcomes. Our sequential Haplo-cord HSCT with ATG/PTCY improved the survival of patients and might be an alternative transplantation approach for patients with relapsed/refractory hematologic malignancies. Frontiers Media S.A. 2021-11-04 /pmc/articles/PMC8599442/ /pubmed/34804017 http://dx.doi.org/10.3389/fimmu.2021.733326 Text en Copyright © 2021 Li, Li, Chen, Li, Chen, Zhu, Wang, Huang, Chen, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Hua Li, Xiaofan Chen, Yiling Li, Duihong Chen, Xianling Zhu, Zhijuan Wang, Yiting Huang, Jiafu Chen, Ping Chen, Yuanzhong Li, Nainong Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies |
title | Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies |
title_full | Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies |
title_fullStr | Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies |
title_full_unstemmed | Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies |
title_short | Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies |
title_sort | sequential transplantation of haploidentical stem cell and unrelated cord blood with using atg/ptcy increases survival of relapsed/refractory hematologic malignancies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599442/ https://www.ncbi.nlm.nih.gov/pubmed/34804017 http://dx.doi.org/10.3389/fimmu.2021.733326 |
work_keys_str_mv | AT lihua sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT lixiaofan sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT chenyiling sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT liduihong sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT chenxianling sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT zhuzhijuan sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT wangyiting sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT huangjiafu sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT chenping sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT chenyuanzhong sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies AT linainong sequentialtransplantationofhaploidenticalstemcellandunrelatedcordbloodwithusingatgptcyincreasessurvivalofrelapsedrefractoryhematologicmalignancies |